Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
DEA establishes specific listing and drug code for hexahydrocannabinol (HHC) as a Schedule I controlled substance, requiring immediate compliance for all entities handling HHC.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Critical. All pharmacies (independent, retail chain, compounding, long-term-care) and any entity handling hexahydrocannabinol (HHC). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately upon publication (May 4, 2026); no grace period.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
HHC is now specifically listed as a Schedule I controlled substance with a DEA drug code, subject to full regulatory requirements including registration, recordkeeping, security, and reporting.
Who it affects
All pharmacies (independent, retail chain, compounding, long-term-care) and any entity handling hexahydrocannabinol (HHC).
What you must do
Ensure all HHC products are treated as Schedule I substances: obtain DEA registration if handling, implement security, maintain records, and report to PDMP where applicable.
Deadline
Immediately upon publication (May 4, 2026); no grace period.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order